(Q46177067)

20 December 2017

title

Inconsistencies and misleading information in officially approved prescribing information from three major drug markets (English)

1 reference

20 December 2017

author name string

B Pfistermeister

1

1 reference

20 December 2017

A Saß

2

1 reference

20 December 2017

M Criegee-Rieck

3

1 reference

20 December 2017

T Bürkle

4

1 reference

20 December 2017

M F Fromm

5

1 reference

20 December 2017

R Maas

6

1 reference

20 December 2017

language of work or name

English

0 references

publication date

25 July 2014

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

96

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

616-624

1 reference

20 December 2017

Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Clinical pharmacology information in summaries of product characteristics and package inserts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Incidence and preventability of adverse drug events in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Consistency in the safety labeling of bioequivalent medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Emergency hospitalizations for adverse drug events in older Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Prescribing information in 26 countries: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Risk, responsibility, and generic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Different indications, warnings and precautions, and contraindications for the same drug-an international comparison of prescribing information for commonly used psychiatric drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

inferred from DOI database lookup

7 January 2021

based on heuristic

A quantitative analysis of adverse events and "overwarning" in drug labeling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

inferred from DOI database lookup

7 January 2021

based on heuristic

The Effectiveness of the Summary of Product Characteristics (SmPC) and Recommendations for Improvement

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.156

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2014.156

1 reference

20 December 2017

1 reference

20 December 2017